Michael H. Serrano-Wu - Department of Chemistry, The Bristol-Myers Squibb Pharmaceutical Research Institute

N. Mainolfi, T. Ehara,R.G. Karki, K. Anderson,A. Mac Sweeney, C. Wiesmann, C. Adams,N. Mainolfi,S.-M. Liao,U.A. Argikar,K. Jendza, C. Zhang,J. Powers, D.W. Klosowski,M. Crowley, T. Kawanami, J. Ding, M. April, C. Forster,M. Serrano-Wu, M. Capparelli, R. Ramqaj,C. Solovay,F. Cumin, T.M. Smith, L. Ferrara, W. Lee, D. Long, M. Prentiss, A. De Erkenez, L. Yang, L. Fang,H. Sellner,F. Sirockin,E. Valeur,P. Erbel,P. Ramage,B. Gerhartz, A. Schubart,S. Flohr,N. Gradoux, R. Feifel, B. Vogg,C. Wiesmann,J. Maibaum, J. Eder,R. Sedrani, R.A. Harrison,M. Mogi, B.D. Jaffee, C.M. Adams

crossref（2020）

Cited0Views0Bibtex

Discovery of 4-((2S,4s)-4-ethoxy-1-((5-methoxy-7-methyl-1h-indol-4-yl)methyl)piperidin-2-yl)benzoic Acid (LNP023), a Factor B Inhibitor Specifically Designed to Be Applicable to Treating a Diverse Array of Complement Mediated Diseases

Journal of medicinal chemistry（2020）

Cited22Views0WOSBibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn